Xience

Manufactured by Abbott

Sourced in United States, Switzerland, Poland

Xience is a medical device developed by Abbott for use in percutaneous coronary intervention procedures. It is a drug-eluting stent that is designed to help open and support blood vessels in the heart.

Automatically generated - may contain errors

Lab products found in correlation

Promus, by Boston Scientific (8 mentions) Resolute onyx, by Medtronic (5 mentions) Orsiro, by Biotronik (4 mentions) Nobori, by Terumo (2 mentions) Ultimaster, by Terumo (2 mentions) Promus element, by Boston Scientific (1 mentions) Sequent please, by B. Braun (1 mentions) Taxus element stent, by Boston Scientific (1 mentions) Xience prime, by Abbott (1 mentions) Cypher select, by Cordis (1 mentions) Taxus express, by Boston Scientific (1 mentions) Magmaris, by Biotronik (1 mentions) Passeo 35, by Biotronik (1 mentions) Dynamic, by Biotronik (1 mentions)

25 protocols using xience

Retrospective Analysis of ACS Patients with EES or R-ZES

Check if the same lab product or an alternative is used in the 5 most similar protocols

We retrospectively analyzed the ACTION-ACS, a pooled large patient ACS database involving
two interventional large-volume academic centers based in Poland: the Department of
Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, and the
Nicolaus Copernicus University, Bydgoszcz, Poland. Information on the follow-up events was
site-reported and adjudicated by a trained physician-investigator. Data of consecutive
patients with ACS, undergoing PCI with EES (Xience, Abbott Vascular, Santa Clara, CA, USA
and Promus Element, Boston Scientific, Natick, MA, USA) or R-ZES (Resolute Integrity,
Resolute Onyx, Medtronic, Fridley, MN, USA), were collected between November 2009 and
February 2017 (Figure 1). Relevant
baseline information, procedural, and clinical outcomes at follow-up were entered into
prespecified electronic case report forms. Angioplasty and stent selection were performed
according to standard techniques at the discretion of the interventional cardiologist. All
patients were prescribed dual antiplatelet therapy (DAPT) consisting of acetylsalicylic
acid, 75 to 100 mg daily, and a P2Y12 inhibitor for at least 1 year according to
guidelines.

Koni E., Wanha W., Ratajczak J., Zhang Z., Podhajski P., Musci R.L., Sangiorgi G.M., Kaźmierski M., Buffon A., Kubica J., Wojakowski W, & Navarese E.P. (2021). Five-Year Comparative Efficacy of Everolimus-Eluting vs. Resolute Zotarolimus-Eluting Stents in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Journal of Clinical Medicine, 10(6), 1278.

+ Open protocol

+ Expand

Dual Antiplatelet Therapy in DES Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols

Adults who were candidates for dual antiplatelet therapy following treatment with FDA-approved drug-eluting or bare metal stents were enrolled. Detailed inclusion and exclusion criteria are listed in the Supplementary Appendix. Each subject provided written informed consent at enrollment.
The primary analytic population and focus of this report is subjects treated with drug-eluting stents only (results in subjects treated with bare metal stents will be reported in a separate publication; see Figure 1). Drug-eluting stents included sirolimus-eluting stents (Cypher, Cordis), zotarolimus-eluting stents (Endeavor, Medtronic), paclitaxel-eluting stents (TAXUS, Boston Scientific), and everolimus-eluting stents (Xience, Abbott Vascular and PROMUS, Boston Scientific). It was recommended that all subjects receive either clopidogrel at a maintenance dose of 75 mg daily or prasugrel at a maintenance dose of 10 mg daily (a dose of 5 mg daily was recommended in subjects weighing less than 60 kg).^{13 (link)} The recommended maintenance aspirin dosage was 75 to 162 mg daily, continued indefinitely.

Mauri L., Kereiakes D.J., Yeh R.W., Driscoll-Shempp P., Cutlip D.E., Steg P.G., Normand S.L., Braunwald E., Wiviott S.D., Cohen D.J., Holmes DR J.r., Krucoff M.W., Hermiller J., Dauerman H.L., Simon D.I., Kandzari D.E., Garratt K.N., Lee D.P., Pow T.K., Lee P.V., Rinaldi M.J, & Massaro J.M. (2014). Twelve or 30 Months of Dual Antiplatelet Therapy After Drug-eluting Stents. The New England journal of medicine, 371(23), 2155-2166.

+ Open protocol

+ Expand

Vascular Healing Assessment Following EES Implantation in Calcified Coronary Stenosis

Check if the same lab product or an alternative is used in the 5 most similar protocols

The study protocol was carried out in accordance with the Declaration of Helsinki and was approved by Ethical Committee of Osaka Metropolitan University Graduate School of Medicine (Approval Number: 2020–271). This retrospective observational study enrolled 31 patients, treated at Osaka Metropolitan University Hospital from June 2015 to June 2021, who fulfilled the following eligibility criteria: (1) patients who underwent PCI using FD-OCT, (2) patients with severely calcified coronary stenosis (calcium arc > 180°), (3) patients who underwent PCI using atherectomy devices (rotational or orbital atherectomy), (4) patients who underwent BP-EES (Synergy, Boston Scientific, Marlborough, MA, USA) or DP-EES (Xience, Abbott Vascular, Santa Clara, CA, USA) implantation, and (5) patients who underwent follow-up coronary angiography and FD-OCT observation of the target vessels in 180 to 730 days after EES implantation, aiming to evaluate the early to mid-term vascular healing. Patients with acute thrombosis in the culprit lesion after PCI were excluded (n = 1). A total of 30 patients with 30 lesions were finally included in the statistical analysis.

Yamaguchi T., Yamazaki T., Yoshida H., Matsumoto K., Yahiro R., Nakao K., Kure Y., Okai T., Shimada T., Otsuka K., Izumiya Y, & Fukuda D. (2023). Tissue responses to everolimus-eluting stents implanted in severely calcified lesions following atherectomy. Cardiovascular Intervention and Therapeutics, 39(1), 34-44.

+ Open protocol

+ Expand

Paclitaxel-iopromide Balloon vs. DES

Check if the same lab product or an alternative is used in the 5 most similar protocols

The different devices are specified in Table 1. As a balloon, the polymer‐free paclitaxel‐iopromide–coated balloon SeQuent Please (B. Braun Melsungen AG, Melsungen, Germany) is used. The DES group consists of 2 stent types: the everolimus‐eluting Xience stent (Abbott Vascular, Santa Clara, CA; also distributed as the Promus stent by Boston Scientific Natick, MA), and the paclitaxel‐eluting Taxus Element stent (Boston Scientific). Initially, the study was started with the paclitaxel‐eluting Taxus Element stent as comparator to use devices with similar agents. However, after inclusion of 20% of patients, the paclitaxel‐eluting stent was no longer available.23, 24 To continue the trial, the steering committee decided to replace the initial comparator stent with the best‐in‐class later‐generation DES (ie, the everolimus‐eluting stent). Accordingly, the sample size was increased to comply with the different efficacy of the 2 comparator stents.

Gilgen N., Farah A., Scheller B., Ohlow M., Mangner N., Weilenmann D., Wöhrle J., Jamshidi P., Leibundgut G., Möbius‐Winkler S., Zweiker R., Krackhardt F., Butter C., Bruch L., Kaiser C., Hoffmann A., Rickenbacher P., Mueller C., Stephan F., Coslovsky M, & Jeger R. (2018). Drug‐coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET‐SMALL 2. Clinical Cardiology, 41(5), 569-575.

+ Open protocol

+ Expand

Optical Coherence Tomography of BVS vs EES

Check if the same lab product or an alternative is used in the 5 most similar protocols

Between March and June 2013, 26 consecutive patients underwent OCT immediately after implantation of 40 BVS (Absorb, Abbott Vascular, Santa Clara, CA, USA). Elective patients as well as patients presenting with acute coronary syndrome (ACS) were included. The OCT data of these patients were retrospectively compared with those of 34 consecutive patients after implantation of 40 metallic everolimus-eluting stents (EES, Xience, Abbott Vascular^, Santa Clara, CA, USA).
Patient characteristics were collected from the medical records of each patient, device characteristics and deployment strategies were collected from the database of the cardiac catheter laboratory. This study was approved by the ethics committee of the Medical University of Vienna and all patients gave their written informed consent.

Dalos D., Gangl C., Roth C., Krenn L., Scherzer S., Vertesich M., Lang I., Maurer G., Neunteufl T., Berger R, & Delle-Karth G. (2016). Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent. BMC Cardiovascular Disorders, 16, 104.

+ Open protocol

+ Expand

Comparative Analysis of Drug-Eluting Stents

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

The second-and third-generation DESs were defined as everolimus-eluting stents with a durable polymer (Xience [Abbott Vascular, Santa Clara, California] and Promus [Boston Scientific, Natick, Massachusetts]), zotarolimus-eluting stents with a durable polymer (Resolute [Medtronic, Minneapolis, Minnesota]), everolimus-eluting stents with a bioabsorbable polymer (Synergy [Boston Scientific, Natick, Massachusetts]), biolimus-eluting stents with a biodegradable polymer (Nobori [Terumo, Tokyo, Japan]), Ultimaster sirolimus-eluting stents with a biodegradable polymer (Ultimaster [Terumo, Tokyo, Japan] and Orsiro [Biotronik, Bülach, Switzerland]), Biomatrix biolimus A9 (BA9)-eluting stents with a biodegradable polymer, and BioFreedom BA9-coated stents (Biosensors, Newport Beach, California) [3 (link)].

Hsu Y.L., Huang M.S., Chang H.Y., Lee C.H., Chen D.P., Li Y.H., Chao T.H., Liu Y.W, & Liu P.Y. (2023). Application of genetic risk score for in-stent restenosis of second- and third-generation drug-eluting stents in geriatric patients. BMC Geriatrics, 23, 443.

+ Open protocol

+ Expand

Observational Study of PCI in Poland

Check if the same lab product or an alternative is used in the 5 most similar protocols

The data were obtained from a prospective, observational registry of all patients treated with PCI in four interventional cardiology centers in Poland (Sosnowiec, Raciborz, Chorzow, Czestochowa) without cardiac surgery on site. We performed a retrospective screening of unselected individuals (n = 21 400) treated with PCI between 2010 and 2016. We included all consecutive patients with AMI (STEMI and NSTEMI) who underwent single or multi-vessel revascularization with either a BP-SES (ALEX, Balton, Warsaw, Poland) or a DP-EES (XIENCE, Abbott Vascular, Santa Clara, CA) during the index procedure. Relative contributions of the centers in terms of number of patients included were as follows: Czestochowa 39.3%, Sosnowiec 28.8%, Chorzow 16.1% and Raciborz 15.8%. Follow-up data for patients treated in the years 2015–2016 are currently not available. Therefore, for the final analysis only patients treated between 2010 and 2014 were selected, because 1-year follow-up data were available for all the patients. Due to the observational nature of the study and lack of any interference in the diagnostic and therapeutic decision-making process no permission was required from the Institutional Review Board and Bioethics Committee.

Gąsior P., Gierlotka M., Szczurek-Katanski K., Osuch M., Roleder M., Hawranek M., Gasior M., Wojakowski W, & Polonski L. (2018). Safety and efficacy of biodegradable polymer-coated thin strut sirolimus-eluting stent vs. durable polymer-coated everolimus-eluting stent in patients with acute myocardial infarction. Postępy w Kardiologii Interwencyjnej = Advances in Interventional Cardiology, 14(4), 347-355.

+ Open protocol

+ Expand

Comparative Coronary Stent Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Stents for implantation were chosen from first-generation DES durable polymer
based [Paclitaxel-eluting stents (PES) (Taxus, Boston Scientific Corporation,
Maple Grove, MN, USA) or Sirolimus-eluting stent (SES) (Cypher, Cordis, USA)] or
second-generation DES [Everolimus-eluting stent (EES) (Promus, Boston Scientific
Corporation; Xience, Xience Prime, Abbott Vascular, Santa Clara, CA, USA),
Zotarolimus-eluting stent (ZES) (Endeavor, Resolute, Medtronic, Minneapolis, MN,
USA), and Biolimus-eluting stent (BES) (Biolimus A9, Biosensors International,
Switzerland)].

Kawecki D., Morawiec B., Dola J., Waha W., Smolka G., Pluta A., Marcinkiewicz K., Ochała A., Nowalany-Kozielska E, & Wojakowski W. (2016). First- Versus Second-Generation Drug-Eluting Stents in Acute Coronary Syndromes (Katowice-Zabrze Registry). Arquivos Brasileiros de Cardiologia, 106(5), 373-381.

+ Open protocol

+ Expand

Durable vs. Biodegradable Polymer DES Performance

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following stents in the ROCK registry had durable polymers and were analyzed as the DP-DES group: 1. Xience (Abbott Vascular, Santa Clara, CA, USA), a cobalt chromium everolimus eluting stent (CoCr-EES) with strut thickness 81 μm. (n = 99) 2. Resolute Onyx (Medtronic, Santa Rosa, CA, USA), a zotarolimus eluting stent (ZES) with strut thickness 81 μm. (n = 61) 3. Endeavor (Medtronic, Santa Rosa, CA, USA), a ZES with strut thickness 91 μm. (n = 32) 4. Promus (Boston Scientific, Marlborough, MA, USA), a platinum chromium everolimus eluting stent (PtCr-EES) with strut thickness 81 μm (n = 80).
Meanwhile, the following stents in the ROCK registry had biodegradable polymers and were analyzed as the DP-DES group: 1. Ultimaster (Terumo, Tokyo, Japan), a cobalt chromium sirolimus eluting stent (CoCr-SES) with strut thickness 80 μm. (n = 44) 2. Orsiro (Biotronik, Berlin, Germany), a CoCr-SES with strut thickness 60 μm for stent diameter 2.25–3.0 mm and 80 μm for larger diameters. (n = 31) 3. Synergy (Boston Scientific, Marlborough, MA, USA), a platinum chromium everolimus eluting stent (PtCr-EES) with strut thickness 74 μm. (n = 150) 4. Nobori (Terumo, Tokyo, Japan), a stainless steel biolimus eluting stent (BES) with strut thickness 112 μm. (n = 6) 5. Biomatrix (Biosensors International, Morges, Switzerland), a CoCr-BES with strut thickness 83 μm (n = 7).

Kim K.A., Her S.H., Lee K., Choi I.J., Lee J.H., Lee J.H., Lee S.R., Lee P.H., Lee S.W., Yoo K.D., Lee S.N., Jang W.Y., Moon D., Moon K.W., Yun K.H, & Lee H.J. (2022). Clinical Outcomes of Biodegradable versus Durable Polymer Drug Eluting Stents in Rotational Atherectomy: Results from ROCK Registry. Journal of Clinical Medicine, 11(21), 6251.

+ Open protocol

+ Expand

Coronary Stent Restenosis Patterns

Check if the same lab product or an alternative is used in the 5 most similar protocols

A total of 66 ISR lesions were identified in 41 consecutive patients enrolled in this study. We found 44 ISR within G1 DES: 21 sirolimus-eluting stents (SES) (Cypher SELECT, Cordis, Miami Lakes, FL, USA) and 23 paclitaxel-eluting stents (PES) (Taxus EXPRESS and Liberté, Boston Scientific, Natick, MA, USA). We also identified 22 ISR lesions in G2 DES: of which 11 everolimus-eluting stents (EES) (9 Xience, Abbott Vascular, Santa Clara, CA, USA; and 2 Promus, Boston Scientific, Natick, MA, USA) 10 zotarolimus-eluting stents (ZES) (Resolute, Medtronic, Santa Rosa, CA, USA) and 1 biolimus-eluting stent (BES) (BioMatrix Flex, Biosensors Inc, Newport Beach, CA, USA) (Fig. 3). Coronary angiography was clinically driven in 58.2% of cases and electively scheduled in the remaining. Only 5 lesions (7.6%) required balloon pre-dilatation before OCT pullback.Fig. 3

Schematic view of enrolled stents, according to generation, eluted drug and brand. For acronyms see “Results” chapter.

Kilickesmez K., Dall'Ara G., Rama-Merchan J.C., Ghione M., Mattesini A., Vinues C.M., Konstantinidis N., Pighi M., Estevez-Loureiro R., Zivelonghi C., Lindsay A.C., Secco G.G., Foin N., De Silva R, & Di Mario C. (2014). Optical coherence tomography characteristics of in-stent restenosis are different between first and second generation drug eluting stents. International Journal of Cardiology. Heart & Vessels, 3, 68-74.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!